固有的光显示了新型Janus激酶3抑制剂的免疫特征
Julian Laux1,2, Mariella Martorelli1,2, Simon Strass1
1Synovo GmbH, Paul-Ehrlich-Straße 15, Tübingen 72076, Germany.
ACS pharmacology & translational science
|October 19, 2023
概括
这项研究表明,血中的药物度并不能准确地反映目标部位的药物量. 阿扎利德宏化物集中在肺部和肠道上皮质中,这表明在粘膜中的疗效比血水平更高.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物物理学的生物物理.
- 细胞生物学 细胞生物学
背景情况:
- 了解药物在目标地点的分布对于准确的疗效评估至关重要.
- 血液和血中药物的明显度可能与作用部位的实际药物度无关.
- 研究化合物特性与器官/亚细胞分布之间的关系至关重要.
研究的目的:
- 研究小分子的物理性质,明显体积度和器官/亚细胞分布之间的关系.
- 为了确定血或全血药物度是否低估了特定组织中的水平.
- 探索光JAK3连接体及其宏类结合体的分布模式.
主要方法:
- 使用固有的光JAK3配体和类结合物.
- 在免疫细胞中进行了体外吸收研究.
- 分析了使用质谱和冷显微镜的小鼠药理动力学样本.
- 检查了器官和亚细胞分布,没有固定器件.
主要成果:
- 试验室研究表明物质与免疫细胞中的颗粒或有机体有关.
- 低温光显微镜在体内证实了颗粒的吸收,与体外观察结果一致.
- 库马林-化和携带JAK3抑制剂的宏化物分布模式相似.
- 阿扎利德宏化物显示出在肺部和肠道上皮质中缩的倾向.
- 血/全血估计可能低估了粘膜中的宏化物度.
结论:
- 药物分发受到宏化物等较大分子的特性显著的影响.
- 阿扎利德宏化物积聚在肺部和肠道上皮质中,特别是粘膜中.
- 在屏障组织中观察到较高的药物水平可能解释了细菌静止剂量下的疗效.
- 目前的血/血液度估计可能不准确地反映这些关键区域的药物水平.
更多相关视频
04:47A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
Published on: February 23, 2018
7.8K
06:46Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
Published on: May 8, 2017
8.8K
相关概念视频
01:12Immunofluorescence Microscopy
10.5K
A fluorescence microscope uses fluorescent chromophores called fluorochromes, which can absorb energy from a light source and then emit this energy as visible light. Fluorochromes include naturally fluorescent substances (such as chlorophylls) and fluorescent stains that are added to the specimen to create contrast. Dyes such as Texas red and FITC are examples of fluorochromes. Other examples include the nucleic acid dyes 4’,6’-diamidino-2-phenylindole (DAPI), and acridine orange.
10.5K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K